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1. Introduction
Gene therapies have enormous potential to cure human disease. In recent years, hematopoiet‐
ic stem cell (HSC) gene therapy has advanced tremendously, due in part to years of intense re‐
search to develop effective vectors and efficient  ex vivo transduction protocols.  In early
clinical trials, inefficient gene transfer resulted in either a lack of therapeutic benefit or short-
lived therapeutic benefit [1-3]. Advances in preclinical animal models, led to improved gene
transfer in human clinical trials, where long-term efficacy has now been achieved. HSC gene
therapy has been used to correct several monoallelic genetic diseases [4], such as X-linked se‐
vere combined immune-deficiency (SCID X-1) [5],  chronic granulomatous disease (CGD)
[6-8], adenine deaminase deficiency (ADA-SCID) [9-12], Wiskott-Aldrich syndrome [13-14],
and X-linked adrenoleukodysrophy [15,16]. Recently HSC gene therapy has also been used to
treat glioblastoma [17], X-linked hyper-immunoglobulin M syndrome (HIGM), and familial
haemophagocyticlymphohistiocytosis syndrome (HLH) [18]. These successes are in large part
due to advances in ex vivo transduction protocols and improvements with recombinant vec‐
tor technologies. The French SCID-X1 HSC gene therapy trial marked a major turning point in
the field when nine of the ten patients treated exhibited therapeutic benefit. However, follow‐
ing this exciting achievement the field was dealt a major setback when it was initially report‐
ed, that two patients from the study had developed vector-mediated leukemia resulting from
the treatment [19]. This was the first vector-mediated malignancy reported in a HSC gene
therapy clinical trial. Four boys ultimately developed leukemia as a side effect of the gene
therapy procedure [5]. Three of the four boys were successfully treated with chemotherapy,
but one patient died due to vector-mediated T cell leukemia. In these patients, vector-mediat‐
ed dysregulation of host genes led to leukemia, and this unwanted adverse side effect is cur‐
rently a major challenge for HSC gene therapy. The effect of the integrated viral vector on host
gene expression resulting in an altered phenotype is known as genotoxicity.
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Genotoxicity is a result of retroviral mediated delivery of the integrated form of the retrovi‐
ral vector genome known as the vector provirus into the host genome. Integration of the
vector provirus into a host chromosome, by definition, alters the host DNA. In cases where a
retrovirus or retroviral vector provirus has dysregulated host gene expression, insertional
mutagenesis is said to have occurred. However, it is important to remember that provirus
integration always results in mutation of the host genome, regardless of whether the vector
provirus exerts an effect on host gene expression. The oncogenic properties of replication-
competent retroviruses were well known prior to the development of retroviral vectors for
gene therapy. However, vectors that are used in gene therapy have been engineered so that
they do not have the ability to replicate, only to insert their genome into a target cell. These
vectors are thus referred to as replication-incompetent. In numerous preclinical and clinical
studies conducted prior to the SCID-X1 trial, malignancies were not observed when using
replication-incompetent vector systems [20]. It was therefore assumed that the potential for
malignant transformation from a replication-incompetent vector was very low. Unfortunate‐
ly, it has now been clearly shown in the French SCID-X1 trial and in subsequent HSC gene
therapy trials, that genotoxicity is indeed a problem for replication-incompetent vectors.
Here we review the mechanisms of vector-mediated genotoxicity in HSC gene therapy and
describe efforts in the field to reduce genotoxicity which is currently a major challenge in the
field [21, 22].
2. Why integrating vectors are used for HSC gene therapy
Why use integrating vectors for HSC gene therapy if we know that retroviral vectors muta‐
genize the genome and therefore carry a risk to induce genotoxicity? The answer is that pro‐
virus integration to HSCs is currently the only way to efficiently and stably deliver
transgenes to the billions of mature blood cells produced every day in the body. Our mature
blood cells are generated from a relatively small pool of self-renewing long term-repopulat‐
ing HSCs in the bone marrow through a process known as hematopoiesis (Figure 1). During
hematopoiesis, long-term repopulating stem cells provide lifelong supplies of the mature
cells of each blood cell lineage via massive expansion of transit-amplifying cells that include
multi-potent and lineage restricted progenitors. By permanently modifying a long term re‐
populating HSC via proviral integration into the HSC genome we can ensure that all proge‐
ny produced from these gene-modified cells will inherit the transgene during mitosis. Thus,
the mature blood cells that arise during hematopoiesis from gene-modified HSCs and their
daughter transit amplifying cells all inherit the transgene. Using retroviral vectors to effi‐
ciently deliver a therapeutic transgene via integration of the vector provirus into a HSC is
currently the only effective approach for HSC gene therapy. While there have been reports
of some success with adenovirus and other non-integrating approaches in small animal
models, to date only integrating vectors have been used successfully for HSC gene therapy
in large animal models and in clinical trials.
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Figure 1. Human Hematopoiesis. Long-term-hematopoietic stem cells (LT-HSCs) are a self-renewing population of
stem cells that reconstitute the blood system throughout the entirety of our life span. Short-term-HSCs, reconstitute
our blood system for only limited periods. The short-term-HSCs differentiate into multipotent progenitors (MPPs),
which have the ability to differentiate into several transit amplifying cell lineages. Common lymphoid progenitors
(CLPs) differentiate into (Pro- Dendritic Cell, Pro-T, Pro-NK, and Pro-B) lymphoid progenitor cells. Finally, these progeni‐
tors give rise to the mature lymphoid class cells of the blood system (T- lymphocytes, B-lymphocytes, and natural killer
(NK) cells). Common myeloid progenitors (CMPs), give rise to granulocyte-macrophage progenitors (GMPs) and mega‐
karyocyte-erythroid progenitors (MEPs) that differentiate into :( macrophages, granulocytes, megakaryocytes, and er‐
ythroid) myeloid class progenitors. Finally, these progenitors give rise to the mature myeloid class cells of the blood
system.
3. Retroviruses as insertional mutagens
We now know that the use of retroviral vectors for HSC gene therapy, though highly effi‐
cient, can dysregulate host genes near the vector provirus and ultimately lead to malignant
transformation. The ability of replicating retroviruses to cause tumorigenesis is well estab‐
lished. In 1911, Peyton Rous showed that a sarcoma growing on a domestic chicken could be
transferred to another chicken by exposing the healthy bird to a cell-free filtrate [23]. This
filterable agent is now known to be the Rous sarcoma retrovirus. Since this report, many ret‐
roviruses have been discovered that cause diverse malignancies. There are several mecha‐
nisms whereby retroviruses can cause malignancy. Varmus et al. showed that acutely
transforming onco-retroviruses capture and deliver cellular oncogenes, which allow these
viruses to efficiently, convert target cells into a malignant phenotype [24]. It is important to
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note that oncogene capture does not occur at a detectable frequency with current replica‐
tion-incompetent vectors used in gene therapy. Yet several mechanisms remain for cellular
transformation from replication-incompetent retroviral vector proviruses (Figure 2). Despite
the risks associated with malignant transformation from retroviral vectors via insertional
mutagenesis, for several severe hematopoietic diseases the therapeutic benefit of HSC gene
therapy outweighs the risks. Currently, major efforts are underway to further our under‐
standing of genotoxic events and to improve vector safety by reducing their genotoxic po‐
tential [18, 25, 26].
Figure 2. Mechanisms of Retroviral Mutagenesis. The black boxes represent promoters, and grey squares represent
exons. A) The proviral 3’ LTR can drive transcription of nearby cellular gene at an increased rate. B) Proviral LTR en‐
hancers can activate a nearby promoter, increasing transcription of cellular genes. C) Transcription from 5’ LTR in con‐
junction with proviral cryptic splice sights creates novel isoforms and fusion transcripts of both cellular and viral genes.
D) Proviral LTR methylation, induces epigenetic changes, silencing proviral genes and nearby cellular genes. E) Proviral
integration can disrupt cellular gene expression by causing premature polyadenylation (pA) signaling.
4. Overview of ex vivo HSC gene therapy
It is important when studying genotoxicity to consider how the target cells are manipulated
during the gene transfer process. HSC gene therapy is conceptually straightforward but re‐
quires culture of stem cells under the appropriate ex vivo conditions. A patient’s cells are
collected and enriched for repopulating stem cells using the CD34 marker. The CD34 pro‐
tein is a member of the sialomucin family, and is expressed in early HSCs [27]. The CD34
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marker allows for rapid enrichment of HSCs, typically via column enrichment using CD34
antibody-conjugated magnetic beads. CD34-enriched cells that include repopulating HSCs
are then exposed to the vector containing the therapeutic gene in an ex vivo transduction
process. Following ex vivo transduction, gene modified cells must be infused into the pa‐
tient. Correction of the disease phenotype will occur if enough gene-modified repopulating
cells engraft. Engraftment requires that gene modified cells survive, home to the bone mar‐
row, and proliferate sufficiently to repopulate the blood system.
Early preclinical HSC gene therapy studies in mice demonstrated high gene transfer rates.
However, early clinical trials using similar approaches and culture conditions had inefficient
gene transfer [28, 29]. Large animal models such as the dog and non-human primates more
accurately model human HSC gene therapy and have since been used to establish the condi‐
tions for efficient ex vivo transduction [30]. More effective ex vivo gene protocols were de‐
veloped, that resulted in higher gene transfer efficiencies while maintaining efficient
engraftment. These improvements included defining cytokine support and the extracellular
matrix CH-296 fibronectin fragment [5, 31, 32]. Together these advances contributed to the
success of HSC gene therapy clinical trials such as the French SCID-X1 trial, and now effi‐
cient transduction of human CD34+ cells can be routinely achieved using retroviral vectors.
These improved gene transfer efficiencies also factored into the observed genotoxicity. For
example, two patients in the French SCID-X1 trials were estimated to have a total of 4.3 × 106
and 11.3 × 106 CD34+γC + cells/kg body weight gene modified cells respectively [5]. Thus in
each of these patients many proviral integrants exist with the potential to dysregulate many
nearby genes, including proto-oncogenes.
5. The SCID-X1 trials as an example of genotoxicity in HSC gene therapy
SCID-X1 is a fatal X-linked inherited mutation of the IL2RG locus harboring the gamma c
(γC) cytokine receptor  common subunit  [5].  Inactivating mutations in this  gene prevent
proper cellular communication and maturation of lymphoid progenitor cells.  The loss of
cellular  signaling  in  lymphoid  progenitors  prevents  the  development  of  mature  T,  NK,
and B cells. Many SCID-X1 patients fail to thrive or suffer morbidity and mortality in ear‐
ly life because of impaired immune function, which leaves them susceptible to life-threat‐
ening infection. Allogeneic HSC transplantation has been used to treat SCID-X1, but many
patients  do  not  have  suitable  donors.  In  addition,  graft  versus  host  disease  is  a  major
source of mortality for patients treated by this approach. Graft versus host disease occurs
when transplanted (allogeneic) immune cells from a donor recognize the host recipient tis‐
sue as foreign and attack these cells. SCID-X1 HSC gene therapy using the γC transgene
has a lower mortality rate and a higher treatment efficacy compared to conventional allo‐
geneic bone marrow transplants [25], and is currently the only therapeutic choice for pa‐
tients without a suitable donor. Prior to the French study, preclinical studies conducted in
both murine and canine models corrected SCID-X1 deficiency was with no reported ad‐
verse events [20, 31, 33, and 34].
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In the French SCID-X1 trial, four of the ten patients developed T-cell leukemia from inser‐
tional mutagenesis from the murine moloney leukemia virus (MLV)-based vector [5, 25].
Careful molecular analysis of leukemic cells showed that the MLV provirus integrated near
the proto-oncogene, LMO2, and suggested that viral enhancer elements in the provirus con‐
tributed to leukemia (Figure 2B) [25]. The SCID-X1 trials were the first HSC gene therapy
clinical trial where vector-mediated insertional mutagenesis led to cancer. In this trial, MLV
vector LTR enhancers activated LMO2 expression, resulting in T-cell LMO2 dependent pro‐
liferation (Figure 2B). LMO2 is normally silenced in mature T-cells, and when viral enhanc‐
ers turn on expression, LMO2 drives T-cell proliferation by dysregulating transcription
networks that affect the cell cycle. This promotes cell cycle escape and can result in higher
proliferation rates compared to normal cells [35]. Leukemic transformation was a result of
provirus integration near LMO2 with additional proviral integrants near other proto-onco‐
genes that resulted in expansion of cells with these mutations [5, 19].
6. Clonal expansion in the SCID-X1 trials
As evidenced in the French SCID-X1 trial, retroviral vector integration can dysregulate near‐
by host genes, thus affecting cell growth and survival. Once integrated, elements in the pro‐
virus, particularly enhancers in the LTR, can dysregulate nearby gene expression through
several mechanisms (Figure 2). Aberrant gene expression can dysregulate host cell genes
and regulatory networks involved with cell growth, including proto-oncogenes. A survival
advantage can occur through the activation of proto-oncogenes giving cells a proliferative
advantage or “go signal”. Alternatively, tumor suppressors can be inactivated, causing a
proliferative advantage with uncontrolled cellular division from the lack of a “stop signal”.
To date the genotoxicity described in HSC gene therapy trials has been through activation of
growth promoting genes and proto-oncogenes, rather than inactivation of tumor suppres‐
sors. This is because activation requires a single integration into only one allele whereas in‐
activation of a tumor suppressor requires a second event, either a second integration or a
loss of heterozygosity at that allele, to inactivate tumor suppressor activity. Tumor suppres‐
sors have however been identified in preclinical mouse studies [36-37]. These vector mediat‐
ed mutations along with additional accumulating mutagenic events in expanding gene-
modified repopulating cells can ultimately result in tumorigenesis. The proviral promoter
and enhancer elements have been shown to act up to a distance of 500 Kb upstream and
downstream of the site of proviral integration [38]. In the SCID-X1 trials where patients de‐
veloped T-cell leukemia, the integration sites of dominant repopulating clones near the
genes LMO2, BMI1, HMGA2, SEPT9, RUNX2, and RUNX3 gave rise to cells with a prolifera‐
tive advantage or survival advantage over competitor repopulating cells. These advantages
eventually led to an over-representation of these clones (Figure 3) [5].
We now know how vector-mediated dysregulation of these different genes may have con‐
tributed to clonal expansion and frank leukemia. LMO2 or Lim only 2 is a proto-oncogene
that regulates early progenitor expansion during hematopoiesis [39]. LMO2 oncogenic prop‐
erties were first observed in mature gene-modified T-cells, where it is not normally ex‐
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pressed [39]. However, after proviral integration events, resulting in activation of LMO2,
these gene-modified T-cells begin to expand from dysregulation of transcriptional regulato‐
ry pathways. In 2010, Oram et al. demonstrated that LMO2 expression in T cells activates
FLI1 and ERG enhancers, known to be involved in blood stem/progenitor cells. These gene
products of FLI1 and ERG in turn activate the enhancer of the HHEX/PRH gene locus,
which has been shown to act in early progenitor cell expansion and formation of T-lineage
acute lymphoblastic leukemia (T-ALL) [35]. LMO2 overexpression has also been demon‐
strated to reduce or eliminate cell cyclin dependent kinase (CDK) inhibitors promoting es‐
cape of the G1 cell cycle checkpoints during cellular division [40]. Once aberrantly expressed
within a cell, LMO2 promotes cell cycle progression via multiple mechanisms, giving the
cell a proliferative advantage.
Additional proto-oncogenes were activated in the French SCID-X1 patients. The BMI1 proto-
oncogene normally functions in self-renewal and maintenance of hematopoietic primitive
stem cells [40, 41]. Like LMO2, dysregulation of BMI-1 via enhancer activation results in clo‐
nal expansion. Additional mechanisms mediate clonal expansion, such as the high mobility
group AT-hook2 (HMGA2) which can provide a proliferative advantage when the endoge‐
nous gene is truncated via insertional mutagenesis. Truncation results in the loss of regula‐
tory target sequences within the protein mRNA preventing degradation by the endogenous
miRNA let7. These miRNA elements normally function to regulate HMGA2 via RNA inter‐
ference using the RNA induced silencing complex (RISC) machinery [42]. Truncated
HMGA2 mRNA is not degraded thus continuing activation of gene networks involved with
cell proliferation, and cell-cycle progression [42]. Another mechanism that can contribute to
clonal expansion is the aberrant expression of septin proteins. SEPT9 functions as a microtu‐
bule regulator and plays an important function in cytokinesis and chromosome segregation,
thus affecting genomic stability [43, 44]. When aberrantly expressed, SEPT9 causes dysregu‐
lated cytokinesis or cell division resulting in missegregation of chromosomes [43, 44]. Ge‐
nomic instability then results from SEPT9 dysregulation, leading to the accumulation of
chromosomal deletions or amplifications from missegregation of chromosomes. These
events in conjunction with additional mutations can enhance cell proliferation and survival.
Two additional genes identified near vector proviruses in the SCID-X1 trial were RUNX
family members RUNX2 and RUNX3. RUNX proteins (RUNX 1, 2, 3) are a family of RUNT
homology domain containing α-subunits that form heterodimeric transcription factors that
mediate hematopoietic differentiation and expansion in conjunction with β subunit core
binding factor (CBF). Aberrant expression of the RUNX proteins in mouse models hinders
myeloid class progenitor differentiation capacity and represses expression of several target
genes including Csf1R, Mpo, Cebpd, and the cell cycle inhibitor Cdkn1a [45]. Repression of
these genes blocks hematopoietic stem cell differentiation leading to an accumulation of un‐
differentiated cells. These cells cannot pass the differentiation block to repopulate the de‐
pleted blood cell niche. The lack of differentiated mature cells continues to generate
proliferative signaling pathways that further stimulate mutant HSC expansion. The expand‐
ed undifferentiated blast cells accumulate in the bone marrow, disrupting normal blood cell
production, and can eventually give rise to various cytopenias and leukemic blast crisis.
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Figure 3. Clonal Expansion. A) Patient derivedCD34- enriched hematopoietic stem cells (HSC) population prior to ex
vivo vector exposure. Untransduced cells are blue. B) Polyclonal proviral integration distribution in vector treated HSCs.
This is an ideal proviral distribution, which HSC gene therapy would ideally maintain after infusion into patients. How‐
ever, due to genotoxicity and selection pressures in vivo C) Oligoclonal expansion can be observed, where some clones
expand. In some cases, D) individual clones may harbor a proviral integration near genes promoting a proliferative or
survival advantage, which may eventually contribute to malignancy.
In summary, our current understanding of genotoxicity is that vector proviruses dysregulate
the expression of key regulators of cell cycle, cell survival, genomic stability, proliferative
gene networking and cellular differentiation. This leads to an over-representation of gene-
modified clones with these mutations in the peripheral blood (PB) and bone marrow (BM)
which is referred to as clonal expansion (Figure 3). Clonal expansion can lead to additional
mutations that can eventually cause frank leukemia. The leukemias observed in the French
SCID-X1 trial refocused the gene therapy field to better understand the mechanisms of vector
dysregulation of host genes, with the ultimate goal of reducing the risk of genotoxicity.
7. Risk factors for clonal expansion
It is important to remember that the SCID-X1 trials are one example of clonal expansion in a
specific disease setting using a specific vector type with a specific transgene. Several factors
can influence clonal expansion including the type of vector, vector design, the therapeutic
transgene and the disease setting. For example the transgene in and of itself may provide a
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selective advantage to cells through its expression. This was true in the SCID-X1 trials,
where expression of the corrective γC transgene gave cells a proliferative advantage allow‐
ing reconstitution of the lymphoid cell population from a modest number of gene modified
HSCs [5]. To determine the mechanisms behind these expansion events investigators must
first characterize the integration sites of the vectors being used to deliver the therapeutic
transgene. This allows identification of nearby genes that may have been dysregulated lead‐
ing to clonal expansion.
8. Vector integration sites in expanded repopulating clones allow clonal
tracking
To understand the risk of genotoxicity we need to identify where different vectors tend to
integrate. Conveniently, integrated vector proviruses serve as molecular tags to identify in‐
tegration sites and to track specific clones in order to study clonal expansion. Sequencing the
unique vector-chromosome junctions can identify where in the genome the virus has inte‐
grated. Analysis of vector insertion sites has allowed researchers to compile comprehensive
integration profiles for specific virus types and assess the safety of viral vectors based on the
regions of preferred or recurrent integration.
Long term tracking of gene-modified cells is necessary to monitor potential adverse events
that may occur over time resulting in clonal expansion. By identifying the spectrum of vec‐
tor integration sites in repopulating cells, the clonality of repopulating cells can be estimated
and the expansion of specific clones can be monitored. Long-term tracking may also provide
insight into specific mechanism of clonal expansion, such as emergent LMO2 expansion in
SCID-X1 trials, and will direct novel approaches to reduce genotoxic effects [46]. It has be‐
come an important area of study to understand where retroviruses integrate in the human
genome, thus affecting their safety for use in HSC gene therapy approaches.
9. The integration profile of retroviruses and its relation to genotoxicity
Identifying the integration profiles of different vector types has provided important data on
the relative genotoxic risk associated with different vectors. Following the leukemias ob‐
served in the SCID-X1 trial, integration site distributions were described for different retro‐
viral vectors being developed for gene therapy. Viral integration sites for HIV-1, MLV and
foamy virus (FV) vectors were reported and each exhibits a specific and unique integration
profile. HIV-1 based vectors showed preferences for integration within actively transcribed
genes [47] whereas MLV vectors tends to integrate within transcription start sites near CpG
islands [48-50]. FV vectors also preferentially integrate near transcription start sites and CpG
islands but less frequently than MLV vectors and integrate less frequently in genes than HIV
vectors. The propensity of MLV-based vectors to integrate preferentially very close to pro‐
moter regions was of significant concern since this may increase the risk of dysregulating
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proto-oncogenes. The integration profiles were found to be largely independent of the route
of entry [47, 51, 52] and target cell type [49, 53, 54] although characteristics such as cell cycle
of the target cell can play a minor role in the profile [49,54].
The factors that contribute to the integration profile of viruses and viral vectors are greatly in‐
fluenced by a compliment of host proteins that interact with a poorly defined retroviral pre-in‐
tegration complex (PIC). The PIC is a complex of proteins associated with the viral genome,
and during infection, the PIC must migrate to the nucleus to mediate integration of the reverse-
transcribed viral DNA to generate the vector provirus. This process and the associated proteins
that affect it have been studied using various methods [55-57]. Viral Gag and integrase proteins
have been shown to interact with chromatin, affectively tethering the PIC to specific chromoso‐
mal regions, thus directing integration [57, 58]. Studies have compared the contributions of the
viral integrase and Gag proteins using MLV-HIV chimeras, and shown that both play impor‐
tant roles in integration site specificity [57]. The HIV lens-epithelium-derived growth factor
(LEDGF) is a host derived tethering protein that has been demonstrated to associate with the
PIC and chromatin affecting HIV-1 integration patterns. This host protein has a strong binding
affinity for HIV integrase proteins, which are associated with the lentiviral PIC [59]. The tether‐
ing of the PIC to LEDGF protects the PIC from host enzymatic defenses [56], promotes chroma‐
tin binding [57,  60],  and directs integration site distribution [61].  Unique to foamy virus
biology, the c-terminal end of the Gag protein contains glycine-arginine motifs known as a GR
boxes [62]. These boxes direct viral packaging [63, 64] and nuclear localization [62, 64]. In addi‐
tion to these features, a 13 amino acid motif called the chromatin-binding site (CBS) has been
characterized [58]. This CBS contains a functional binding domain for core histones H2A/H2B
that is thought to tether the PIC to the chromatin after translocation into the nucleus [58]. Host
chromatin tethering proteins often associate with the PIC complex and affect integration site
distributions. Better characterization of cell-virus interaction should enhance our understand‐
ing of viral integration patterns. This has potentially led to novel approaches to direct vector in‐
tegrations to “safe harbor” chromosomal regions, that do not have genes that can lead to clonal
expansion when dysregulated.
10. Methods for integration site analysis
Many methods exist for generating retroviral insertion site data. PCR based techniques include
ligation mediated PCR (LM-PCR Figure 4A), Linear amplification-mediated PCR (LAM-PCR
Figure 4B), and non-restrictive LAM-PCR (nrLAM-PCR Figure 4C). LM-PCR relies on fre‐
quently cutting restriction enzymes to generate fragments that contain the provirus: chromo‐
some junction. These fragments are then ligated to linkers, and after several rounds of PCR, the
resulting products are sequenced. LAM-PCR uses an LTR-specific primer in several rounds of
‘linear’ amplification where the LTR: chromosome junction is amplified. Nested PCR is then
used to produce products that can be directly sequenced or transformed into bacteria and se‐
quenced. nrLAM-PCR is similar to LAM-PCR but uses random shearing rather than digestion
of DNA with restriction enzymes prior to linker ligation and sequencing, thus avoiding restric‐
tion site bias and is currently the gold standard in the field.
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Figure 4. PCR Based LTR: Chromosome Junction Sequencing. A) Demonstration of ligation-mediated PCR, where ge‐
nomic DNA is cut by restriction enzyme digestion, ligated to a linker, and amplified before sequencing of oligos with
an LTR specific primer. B) Left Panel: Linear-amplification-mediated PCR (LAM-PCR) amplifies regions of genomic DNA
containing integrated vector proviruses using an LTR specific primer. The resulting oligos are captured on magnetic
beads and double strand synthesis is performed, followed by restriction enzyme digestion and ligation of a double
stranded linker. Nested PCR is then used and the resulting products sequenced. Right Panel: Non-restrictive linear-am‐
plification-mediated PCR (nrLAM-PCR) amplifies genomic DNA with integrated vector proviruses with an LTR specific
primer. The resulting products are enriched on magnetic beads, followed by single strand linker ligation. Nested PCR is
then employed and the products are sequenced.
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One limitation of the above methods is that PCR bias can affect the frequency of detected
integration sites [65, 66]. Another method that has been used is shuttle vector rescue tech‐
nology, which eliminates PCR-based bias [67, 68, and 54]. In shuttle vector rescue, vector
plasmids encode a bacterial origin of replication and selection gene. DNA fragments that
contain the shuttle vector LTR: chromosome junction are ligated and then transformed into
bacteria. These bacteria can then be grown as colonies to amplify plasmid clones of each po‐
tential insertion site in the absence of PCR based skewing (Figure 5). Plasmid DNA is then
extracted from bacterial colonies and sequenced with an LTR specific primer. In all of the
above methods, aligning the genomic sequence immediately next to the proviral LTR to a
published genome databases allows for identification of the proviral integration site. It will
be interesting to compare the shuttle vector approach to nrLAM-PCR in animal models to
provide information on any potential bias from either technique.
Figure 5. Plasmid Shuttle Vector Rescue. Genomic DNA is presented with vector integrations showing the proviral 5’
LTR, the genetic element encoding a bacterial origin of replications (Ori), and the vector provirus 3’LTR.Vector exposed
cells are lysed and genomic DNA harboring integrated vector proviruses collected. The genomic DNA harboring provi‐
ral integrants is fragmented by restriction enzyme digest, and then self-ligated to form plasmids which may contain
portions of the provirus encoding a bacterial origin of replication and an antibiotic selection gene. These plasmids are
then transformed into E. coli. E. coli transformed with plasmids containing the bacterial origin and antibiotic resistance
gene will form colonies. Sequencing the colony plasmids identifies proviral LTR: chromosome junctions.
11. Animal models to study genotoxicity: Tumor prone mouse models
Animal models allow the in vivo study of the genotoxicity of HSC gene therapy approaches,
within specific disease contexts. These studies are critical because while in vitro genotoxicity
assays can provide important information on the relative genotoxicity of different vectors [50],
only animal models can assess genotoxic effects on in vivo hematopoiesis. Tumor prone mouse
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models have provided important data on the relative genotoxicity of different vectors systems
and have identified genes and gene networks involved in vector-mediated malignant transfor‐
mation [69]. The advantage of tumor prone mice is that the frequency of clonal expansion and
tumorigenesis resulting from vector-mediated genotoxic events is increased, thereby allowing
readout of vector-mediated malignancy within the life span of a mouse.
Several studies have focused on gammaretroviral and lentiviral vectors; testing vectors with
hybrid LTRs from both viral systems to identify the elements responsible for different geno‐
toxicities. These studies, in conjunction with tumor-prone mouse models, have informed
vector design modifications. Enhancer deletion, use of internal housekeeping promoters,
and deletions of vector cryptic splice sites can be used to reduce genotoxic events and im‐
prove safety [69]. The tumor prone cdkn2a-/- mouse model has been used to compare retro‐
viral insertional oncogenic potential using MLV and HIV-based vectors in in vivo
genotoxicity assays [70]. These assays demonstrated HIV- based lentiviral vectors exhibited
an improved safety profile compared to MLV based vectors. The Cdkn2a locus controls cell
senescence and has been shown to prevent cell transformation. Inactivation of this gene pro‐
motes malignancy and has been implicated in almost all types of human cancer [71, 72].
These studies have compared the genotoxic contribution of vector components such as
strong LTR promoters. They have also shown the ability of self-inactivating LTR designs to
reduce genotoxicity.
Although these studies primarily identify activated proto-oncogenes, it is also possible to
identify dysregulated tumor suppressors using retroviral mutagenesis screens [73-75]. Pro‐
viruses can downregulate nearby host gene transcription via host cell methylation of the
proviral LTR that also leads to methylation of the nearby host genes. Identification of the
vector provirus location and nearby host genes can be used to identify haplo-insufficien‐
cies related to malignancy. Recent observations of viral LTR methylation causing proviral
transgene silencing can now be used to identify down regulation of host genes near the
methylated proviral integration sites [75]. The vector LTR methylation events and subse‐
quent silencing of host genes can identify potential tumor suppressors related to vector-
mediated  genotoxicity.  A  recent  study  used  methylation  specific  PCR  and  methylated
DNA immunoprecipitation assays to analyze methylated proviral integrations in mutagen‐
ized mouse tumors [75]. In this study the identification of the methylated and downregu‐
lated gene PTP4A3 in MLV vector-mutagenized murine leukemia samples,  suggests that
haplo-insufficiency may be involved in retroviral  genotoxicity [75].  This  study also sug‐
gests that future studies may identify vector-mediated haploinsufficiency genes that con‐
tribute to genotoxicity.
12. Large animal models of genotoxicity
Large animal models allow long term monitoring of HSC genotoxicity due to the longer life
span of large animals such as dogs and nonhuman primates relative to mice. These models
are important to assess the long-term risks associated with malignant transformation follow‐
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ing insertional mutagenesis from clonal expansion and long-term selection pressures. In two
non-human primate studies, the distribution of MLV-based gammaretroviral and SIV and
HIV-1 based lentiviral integration sites were evaluated over long periods [76, 77]. Clonal ex‐
pansion or malignant transformation was not observed. However, integrants were observed
at higher than expected frequencies near growth promoting genes and proto-oncogenes.
This suggests that repopulating cells with integrations near these genes can influence sur‐
vival of those clones. These studies can shed light on potential mechanisms of clonal expan‐
sion and can allow comparison of different vector types. However, these studies in normal
animals using vectors with a reporter gene that is not expected to provide a selective growth
advantage did not predict the clonal expansion observed in the SCID-X1 trial. This suggests
that large animal models of specific disease settings such as the SCID-X1 dog model [34] will
be important to test improved vectors designed to reduce genotoxicity in a specific disease
setting.
Another important contribution of large animal models has been to improve our under‐
standing of the effects of ex vivo culture on clonal expansion. It has been shown in a nonhu‐
man primate model that genotoxicity can be significantly influenced by the culturing
conditions of gene-modified cells ex vivo. In this study, only six days of culture increased
the incidence of specific clones with gamma retroviral vector integrations near MDS/ EVI1
locus associated with a leukemic phenotype [78]. To monitor the potential effects of ex vivo
culturing condition and in vivo selection on gene-modified repopulating cells, clonal track‐
ing methods must be employed.
13. Tracking of genetically modified clones
The above studies have identified mechanisms of genotoxicity and clonal expansion. During
clinical trials, it is important to monitor potential clonal expansion in order to understand
genotoxicity and to anticipate potential adverse events [79]. As an example, dysregulation of
HMGA2 in a clinical trial for β-thalassemia resulted in clonal expansion of gene-modified
cells that has provided a therapeutic benefit without malignancy to date [80]. β-thalassemia
is a genetic deficiency that hinders β-globin production and patients with this mutation are
reliant upon continued blood transfusions to restore normal blood globin levels. Before HSC
gene therapy the only therapeutic available was allogeneic transplant, however the proce‐
dure is high risk and patient limited due to a lack of matched donors. Thus, patients risk
transplant rejection or development of graft versus host disease. To achieve therapeutic ben‐
efit using HSC gene therapy, lineage specific transgene expression in erythrocytes is re‐
quired, promoting appropriate β-globin expression. Therapeutic benefit was achieved in
two gene therapy patients resulting from a partially dominant clone harboring proviral in‐
sertions near HMGA2 [80]. The authors of this study conclude the clone with HMGA2 may
remain homeostatic or eventually progress through multistep leukemogenesis, indicating a
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strong need for continued gene-marking studies and clonal tracking of these gene-modified
cells in vivo [80].
14. MDS1/EVI1, PRDM16, SETBP1 in trial for CGD
Chronic Granulomatous disease (CGD) is an x-linked inherited immunodeficiency result‐
ing from a mutation in one of  the NADPH oxidase genes [87].  The gp91phox  protein ac‐
counts for 70% of cases [81]. The gp91phox transgene has been used in corrective HSC gene
therapy clinical trials [81]. Unlike SCID-X1 gene-modified cells, CGD gene-modified cells
do not exhibit a proliferative advantage from transgene expression. The lack of condition‐
ing or selection of gene-modified cells contributed to a loss of therapeutic benefit and de‐
tection  of  gene-modified  cells.  Patients  in  the  initial  trials  had  low  marking  with  gene
expression  of  the  corrected  transgene  for  short  periods  of  therapeutic  benefit.  Adverse
genotoxic events developed 2 ½ years after the initial therapy, with clonal expansion and
leukemic transformation [7, 82]. Clonal analysis found activation of MDS1/EVI1, PRDM16,
and SETBP1 proto-oncogenes [81].  One of the patients died in treatment from complica‐
tions arising from the leukemia, the other patient survived after receiving an additional al‐
logeneic  transplant.  In  this  study  there  was  inefficient  engraftment  and  short-term
transgene expression, with vector silencing via vector LTR methylation (Figure 2D) [83].
Further improvements to enhance engraftment and selection of gene-modified cells after
infusion are needed for HSC gene therapy to treat CGD.
15. CCND2 and MDS1/EVI1 trial for Wiskott-Aldrich
HSC gene therapy has also been used in the treatment of Wiskott-Aldrich syndrome (WAS),
an X-linked recessive immune disorder. In this study, patients underwent conditioning with
busulfan to enhance the engraftment of gene-modified cells [84] Patients exhibited therapeu‐
tic benefit, with resolution of disease symptoms, although clonal skewing was detected for
clones that harbored vector integration sites near CCND2 and MDS1/EVI1 [84]. Despite the
high success of WAS HSC gene therapy in nine of the ten patients treated, patient 2 was re‐
ported to have experienced vector-derived genotoxic events after more than 3 years of thera‐
peutic benefit [84], ultimately resulting in T-cell leukemia. The leukemia was a result of
proviral integration near the gene LMO2, and this patient has since been treated with che‐
motherapy resulting in remission [85-87].
Clonal tracking in vivo has recently been employed in a study where patients with glioblas‐
toma were given gene-modified hematopoietic repopulating repopulating stem cells carry‐
ing a methylguanine methyltransferase mutant (MGMT-P140K) [17]. In this approach gene-
modified hematopoietic repopulating cells expressing this mutant enzyme are resistant to
O6-benzylguanine (O6BG). This allows treatment of the glioblastoma solid tumor with
O6BG and an alkylating agent. By protecting the hematopoietic system from chemotherapy-
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mediated hematopoietic toxicity, higher doses of chemotherapy can be used to treat the glio‐
blastoma. In patients undergoing chemotherapy, gene-modified cells were monitored to
track potential clonal expansion and to assess patient safety. Repopulating cells were
tracked and their retroviral integration sites monitored at several different time points, pre-
and post-chemotherapeutic treatment. Throughout the course of chemotherapy treatment,
over 12,000 unique retroviral insertion sites (RISs) were present in the three treated patients.
The heterogeneity of RISs suggests a highly polyclonal engraftment of gene-modified repo‐
pulating cells. During tracking two patients exhibited clonal expansion, with prominent
clones appearing with vector proviruses in PRDM16 (PR domain-containing 16), Set binding
protein 1(SETBP1), and high-mobility group A2 (HMGA2) genes.
In summary, it is clear that HSC gene therapy is an efficacious therapeutic approach, able to
treat debilitating and often fatal genetic deficiencies. However, the observed clonal expan‐
sion in these early clinical trials presents a major concern in the field. There is a need for vec‐
tors with an improved safety profile that are less likely to dysregulate genes and lead to
clonal expansion.
16. Next-generation vectors: Reducing genotoxicity
Extensive efforts are underway to develop vector systems with safer integration profiles and
reduced genotoxic effect. One approach is to retarget vector integration using tethering pro‐
teins that redirect the PIC. Other efforts focus on reducing genotoxicity by producing vec‐
tors less likely to dysregulate nearby genes. Such vectors include self-inactivating LTRs,
which have deleted enhancer elements or U3 regions, preventing enhancer mediated expres‐
sion of nearby genes. Newer vectors are also able to regulate context dependent transgene
expression using insulators and repressor elements to prevent viral promoters from activat‐
ing genes near the site of insertion [88]. Recently investigators have also identified insertion‐
al effects mediating alternative splicing, producing aberrant splice variants and protein
fusion products causing oncogenesis [89, 90]. Modifying the vector-borne cryptic splice sites
in vector backbones can create safer vectors reducing aberrant splice variant, reducing post‐
translational dysregulation of gene expression (Figure 2 C), [89, 91-93]. In addition, vector
and host miRNAs have recently been explored. An example of miRNA control was demon‐
strated using miRNA let7 control elements, regulating expression of transgenes in stem cells
versus somatic cells. Silencing of the transgenes occurs in somatic mature cells by miRNA
cleavage sites. When let7 target sequence is matured and expressed, cleavage of the trans‐
gene containing the target sequence occurs [94]. In pluripotent cells, let7 is not expressed,
thus the target sequences are not cleaved and full-length transgene is expressed [94]. This
technology could potentially direct HSC gene therapy over a major hurdle, by reducing vec‐
tor-born genotoxicity through transgene expression in a highly controlled, cell specific con‐
text. These miRNA technologies have the ability to restrict transgene expression to a specific
cell type and are even able to restrict transgene expression within a specific differentiation
stage of that cell type, allowing a more specific control of transgene delivery, dosage, and
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expression [95]. Incorporation of miRNA technologies can improve vector efficacy and safe‐
ty, ultimately reducing or limiting vector-born genotoxic events.
17. Chromatin insulators
Chromatin insulators are being developed to reduce the propensity of integrated vector pro‐
viruses to dysregulate host gene expression. Insulators are DNA elements that repress the
activity of enhancers on promoters. The chicken hypersensitive site-4 (cHS4] insulator con‐
tains five DNA binding elements within a 250 bp fragment known as the dominant DNase
hypersensitive site [96, 97]. A 650 bp cHS4 element has been characterized in conjunction
with a 400 bp element from cHS4 that can sufficiently block enhancer activation [98]. Addi‐
tional insulators have been described for sea urchin sns5 insulator and an adeno-associated
(AAVS1] viral insulator DHS-S1 [99, 100].
The cHS4 insulator has been used in several retroviral vector systems [80,99, 101-106]. Ini‐
tial studies with cHS4 lentiviral vectors were shown to be effective in reducing genotoxici‐
ty  [107].  Their  use  in  erythrocytes  gave  encouraging  results,  albeit  with  low  titers.  In
addition, this study also demonstrated the effects of insulator failure after a reduction of
cHS4 element repeats, which was reported to have contributed to insertional mutagenesis
and expansion of clones harboring HMGA2 mutations [80]. Sea urchin sns5 is a 462 bp in‐
sulator region that was demonstrated to function in gamma retroviral vectors by maintain‐
ing  chromatin  position  affects  [100].  This  element  also  contains  a  previously  identified
insulator region of  265 bp found to block enhancer-activated directional  transcription in
human  cells  [108,  109].  The  DHS-S1  viral  insulator  has  been  demonstrated  to  increase
transgene expression 1000-fold from an elongation factor 1-alpha (EF1α) promoter in mus‐
cle cells, but was not studied for its ability to block transactivation of host genes [99]. Insu‐
lators can potentially serve several major functions, by protecting against vector silencing,
moderating  vector  variegation  or  uniformity  of  expression,  and  protecting  nearby  host
genes from enhancer activation. Additional studies should help better characterize the effi‐
cacy of insulated vectors
18. Incorporation of cell-type specific control elements
Incorporation of cell-type specific control elements such as erythrocyte specific enhancer-
promoter has been used to control transgene expression [110]. The use of a lineage specific
promoter ensures that transgene expression only occurs within the lineage from which the
promoter is active. Moreover, avoiding expression of the transgene in other cell types with
which the promoter is not active. The premise of lineage-restricted promoters for HSC gene
therapy is that they may eliminate or reduce genotoxicity resulting from dysregulation of
genes in stem/progenitor cells. This is accomplished by activating transgene expression only
in a cell lineage with which transgene expression is required for therapeutic benefit. This ap‐
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proach might protect primitive cells from dysregulation, as the promoter is not expressed
until differentiation into the target cell type. This is an attractive area of research for diseases
that characteristically are exhibited in one lineage of the blood system such as hemaglobino‐
pathies. This approach was used in a thalassemia trial, where a β-locus-control-region-de‐
rived promoter was used [80]. The transgene is delivered to long term repopulating HSCs,
but the promoter is not active. Only after erythroid differentiation would the enhancer be‐
come active, resulting in transgene expression in erythrocytes. This may reduce the occur‐
rence of proto-oncogene activation in stem/progenitor cells. Other lineage specific promoters
are being studied, including B cell lineage specific promoters [111]. When a lineage specific
promoter is not a viable option, vectors may need to be targeted to specific regions of the
chromatin, where vector insertion is at a much lower risk of causing malignancy.
19. Re-targeting of retroviral vectors
Efforts have been made to target retroviral proviruses to specific chromosomal locations.
LEDGF, a host cell protein that interacts with HIV Gag has been used to effect tethering and
targeting of viral integration Gijsbers et al [112]. In this study, cells were modified to express
LEDGF protein containing a chromatin-interacting domain of chromobox homolog 1
(CBX1), which binds di- and tri- methylated regions of histone 3 (H3) in heterochromatic re‐
gions of the genome [112]. H3s are located pericentric to regions of heterochromatin, which
is safer in terms of insertional mutagenesis as genes in these regions are normally silent.
However, the reporting of significant retargeting of integration sites to heterochromatin is
encouraging.
In addition, authors reported that transgene expression was not affected by targeting to
these transcriptionally unfavorable heterochromatic sites [112]. These exciting experiments
have demonstrated that vectors containing Gag and Pol C termini with adapted or unique
binding domains could direct insertional distribution [113]. However, LEDGF cannot be
modified in HSC gene therapy and alternative tethering approaches must be devised.
Additional tethering proteins have been studied and need to be fully characterized to ex‐
pand targeted integration locations in in vivo approaches [113]. In future studies use of ap‐
propriate tethers for modified integration site preference may reduce genotoxicity and may
provide a better understanding of virus and host interactions affecting viral integration. In
addition, even with vector systems that have incorporated these safety mechanisms, geno‐
toxic events may arise and methods to ablate the gene-modified cells will be useful to avoid
malignancy.
20. Approaches to ablate expanded cell clones
Several approaches exist to ablate or control expanded clones after insertionally activated
oncogenesis has occurred. Conditional selection systems have been employed to control the
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longevity and survival of HSC gene-modified clones after infusion. Several conditional pro‐
moter systems such as TET on/off and pro-drug inducible expression cassettes have been
used to target cancer cells harboring dangerous integrations through vector silencing and
suicide gene activation [114].
The tetracycline (Tet) on/off gene expression system utilizes a pro-drug to regulate trans‐
gene expression by modifying a Tet repressor protein (TetR). TetR is constitutively ex‐
pressed and depending on its conformation will either be bound to the tetracycline operator
(TetO), or unbound. In a Tet on system, TetR does not bind TetO until administration of the
pro-drug, typically doxycycline. Once the pro-drug is administered, TetR actively binds Te‐
tO and silences transcription of nearby transgenes. In the absence of the pro-drug TetR can‐
not bind TetO, and this region of the genome is no longer blocked from transcription, and
gene expression resumes. Alternatively, modifications have been made to TetR, allowing it
to bind to repressor sequences until it is deactivated by a pro-drug; this system is called Tet
off. The Tet on/off system may be used in conjunction with suicide genes to ablate undesired
clones.
In gene suicide approaches, HSC gene therapy delivers an active transgene in conjunction
with a pro-drug induced suicide gene such as Thymidine Kinase [115]. In the event that
transformations result from insertional mutagenesis and clonal expansion, clones harboring
integrations can be eliminated or reduced by activating expression of the suicide gene, in‐
ducing apoptosis and eliminating clones harboring proviral integrations [26]. Recent clinical
trials using an inducible caspase 9 (iCasp9), which remains in an inactivated state until di‐
merization following treatment with AP1903 small molecule, was reported in four patients
with graft versus host disease after gene-modified hematopoietic transfusion [116]. In four
patients, a single infusion of AP1903 was reported to have eliminated 90% of gene modified
T cells within 30 minutes of administration of the inducing drug AP1903. GVHD and other
associated illnesses typically observed after allogeneic bone marrow transplants were not
detected up to a year after AP1903 treatment [116]. Thymidine kinase and iCasp9 present
effective safety switches to control an array of genotoxic effects arising from HSC gene ther‐
apy [26, 117]. Utilizing these safety mechanisms in new vector designs will aid in furthering
safety and reducing genotoxic events, and allow for selective ablation of expanded gene-
modified clones in vivo.
21. Concluding summary
The use of HSC gene therapy in clinical trials is expanding, and the therapeutic potential is
enormous. Following the initial successes with ADA SCID and SCID-X1 additional effica‐
cious therapies were reported for WAS, β-thalassemia, and CGD. Seymour et al. reported
that the majority of over 90 patients receiving HSC gene therapy exhibit prolonged clinical
benefit, with greater than 90% survival rate despite the occurrence of genotoxic events [46].
Current studies that are underway aim to characterize and reduce genotoxicity. Several ap‐
proaches have reduced genotoxic events in preclinical studies. With ongoing technological
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refinement, newer and safer HSC gene therapy vectors are entering, or will soon enter, the
clinical arena. These advances are crucial for HSC gene therapy to enter mainstream medi‐
cine as an effective and safe therapeutic approach.
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